Literature DB >> 30851343

Identification of IgG1 Aggregation Initiation Region by Hydrogen Deuterium Mass Spectrometry.

Masanori Noda1, Kentaro Ishii2, Mika Yamauchi1, Hiroaki Oyama1, Takashi Tadokoro3, Katsumi Maenaka3, Tetsuo Torisu1, Susumu Uchiyama4.   

Abstract

Antibody aggregates are a potential risk for immunogenicity; therefore, rational approaches to improve associated aggregation properties need to be developed. Here, we report the amino acid region responsible for aggregation initiation. Two types of therapeutic IgG1 antibody monomer samples were prepared: IgG1 mAb40-3M stored at 40°C for 3 months, which existed in monodisperse state, and the monomer mAb65-5m, which was dissociated from small soluble aggregates by heating at 65°C for 5 min. Hydrogen deuterium exchange mass spectrometry of mAb40-3M identified 2 sites in the Fc region (site 1, F239-M256; site 2, S428-G450) with increased exchange rates. Site 1 includes a region reported as being susceptible to structural change induced by stress. Exposure of site 1 was undetected after 2 months of storage at 40°C but was subsequently detectable after 3 months. As site 2 is spatially close to site 1, the structural change of site 1 could propagate site 2. Besides these 2 regions, hydrogen deuterium exchange mass spectrometry of mAb65-5m identified an exposure of I257-W281 in Fc (site 3), within which a peptide sequence with high aggregation tendency was discovered. We thus concluded that exposure of site 3 is a trigger for the association of a partially denatured antibody.
Copyright © 2019 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IgG aggregation; adalimumab; conformational stability; differential scanning calorimetry; hydrogen deuterium exchange mass spectrometry

Mesh:

Substances:

Year:  2019        PMID: 30851343     DOI: 10.1016/j.xphs.2019.02.023

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Pro108Ser mutation of SARS-CoV-2 3CLpro reduces the enzyme activity and ameliorates the clinical severity of COVID-19.

Authors:  Kodai Abe; Yasuaki Kabe; Susumu Uchiyama; Yuka W Iwasaki; Hirotsugu Ishizu; Yoshifumi Uwamino; Toshiki Takenouchi; Shunsuke Uno; Makoto Ishii; Takahiro Maruno; Masanori Noda; Mitsuru Murata; Naoki Hasegawa; Hideyuki Saya; Yuko Kitagawa; Koichi Fukunaga; Masayuki Amagai; Haruhiko Siomi; Makoto Suematsu; Kenjiro Kosaki
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

2.  The Fab portion of immunoglobulin G has sites in the CL domain that interact with Fc gamma receptor IIIa.

Authors:  Yuki Yamaguchi; Natsumi Wakaizumi; Mine Irisa; Takahiro Maruno; Mari Shimada; Koya Shintani; Haruka Nishiumi; Rina Yogo; Saeko Yanaka; Daisuke Higo; Tetsuo Torisu; Koichi Kato; Susumu Uchiyama
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 5.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.